LioCyx-M004 for HBV-Related Hepatocellular Carcinoma Earns Fast Track Designation
source: pixabay.com

LioCyx-M004 for HBV-Related Hepatocellular Carcinoma Earns Fast Track Designation

  According to Healio, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to LioCyx-M004. This therapy, developed by T-cell immunotherapy company Lion TCR, is designed to…

Continue Reading LioCyx-M004 for HBV-Related Hepatocellular Carcinoma Earns Fast Track Designation
FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment
Source: Pixabay.com

FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment

According to a press release from Eiger Biopharmaceuticals, the American Food and Drug Administration (FDA) recently granted the Company's experimental hepatitis delta virus drug (hepatitis D), peginterferon lambda, breakthrough therapy…

Continue Reading FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment